First-line (1L) zolbetuximab plus chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT plus GLOW

被引：0

作者：

Kang, Y-K. ^{[1
]}

Shah, M. A. ^{[2
]}

Shitara, K. ^{[3
]}

Ajani, J. A. ^{[4
]}

Lordick, F. ^{[5
]}

Van Cutsem, E. ^{[6
]}

Ilson, D. H. ^{[7
]}

Klempner, S. J. ^{[8
]}

Yamaguchi, K. ^{[9
]}

Nakajima, T. ^{[10
]}

Cao, Y. J. ^{[11
]}

Li, R. ^{[12
]}

Moran, D. ^{[11
]}

Pophale, R. R. ^{[13
]}

Ranganath, R. ^{[13
]}

Xu, R-H. ^{[14
]}

机构：

[1] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[2] Weill Cornell Med Coll, Med Oncol & Hematol Dept, New York, NY USA

[3] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[4] Univ Texas MD Anderson Canc Ctr, GI Med Oncol, Houston, TX USA

[5] Univ Krebszentrum Leipzig, Univ Klinikum Leipzig, Med Dept, Leipzig, Germany

[6] UZ Leuven, Univ Hosp Leuven, Digest Oncol Dept, Campus Gasthuisberg, Leuven, Belgium

[7] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Dept Med, New York, NY USA

[8] MGH Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA USA

[9] Canc Inst Hosp JFCR, Gastroenterol Chemotherapy Dept, Koto Ku, Tokyo, Japan

[10] Astellas Pharma Global Dev, Med Dept, Northbrook, IL USA

[11] Astellas Pharma Global Dev Inc, Data Sci, Northbrook, IL USA

[12] Astellas Pharma Global Dev, Data Sci, Northbrook, IL USA

[13] Astellas Pharma Global Dev Inc, Med Affairs Dept, Northbrook, IL USA

[14] Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1438P

引用

页码：S895 / S895

页数：1

共 50 条

[41] A randomized phase II clinical trial evaluating the safety and efficacy of initial dose adjustment of zolbetuximab plus chemotherapy in patients with HER2-negative and CLDN18.2-positive unresectable advanced or recurrent gastric, gastroesophageal junction cancer or esophageal adenocarcinoma (GENTLE-Z).
Okunaka, Mashiro
Furuoka, Momoka
Wakabayashi, Masashi
Furuya, Hideki
Bando, Hideaki
Shitara, Kohei
Nakayama, Izuma
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS504 - TPS504
[42] Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Lowery, M.
Wyrwicz, L.
Oh, D-Y.
Shiu, K. K.
Weber, P. Yanez
Bai, Y.
Lee, J.
Rivera, F.
Alves, G.
Garrido, M.
Fernandez, M. Gonzalez
Li, J.
Cil, T.
Cruz, F.
Qin, S.
Yin, L.
Valderrama, A.
Bordia, S.
Rha, S. Y.
ANNALS OF ONCOLOGY, 2023, 34 : S854 - S855
[43] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (vol 401, pg 1655, 2023)
Shitara, K.
Lordick, F.
Bang, Y-J
LANCET, 2023, 402 (10398): : 290 - 290
[44] A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab plus chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA)
Klempner, Samuel J.
Sonbol, Bassam Bassam
Wainberg, Zev A.
Uronis, Hope Elizabeth
Chiu, Vi Kien
Scott, Aaron James
Iqbal, Syma
Tejani, Mohamedtaki Abdulaziz
Stilian, Melissa C.
Thoma, Mathis
Kagey, Michael
Baum, Jason
Sirard, Cynthia A.
Altura, Rachel A.
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[45] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Xu, R-H.
Oh, D-Y.
Kato, K.
Arkenau, T.
Tabernero, J.
Cruz-Correa, M.
Zimina, A.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Spigel, D. R.
Wyrwicz, L. S.
Cid, R. A. Pazo
Li, L.
Xu, Y.
McHenry, M. B.
Yang, S.
Moehler, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1320 - S1321
[46] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Xu, R-H.
Oh, D-Y.
Kato, K.
Arkenau, H-T.
Tabernero, J.
Cruz-Correa, M.
Zimina, A. V.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Spigel, D. R.
Wyrwicz, L. S.
Pazo Cid, R. A.
Li, L.
Xu, Y.
McHenry, M. B.
Yang, S.
Moehler, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
[47] Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)
Sugarman, Ryan
Nunna, Sasikiran
Betts, Keith A.
Nie, Xiaoyu
Nguyen, Hiep
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[48] First-line (1L) fuzuloparib plus mfolfirinox followed by maintenance fuzuloparib in patients (pts) with unresectable locally advanced or metastatic (LA/M) pancreatic cancer (PC): A phase Ib study
Yu, X.
Mou, Y.
Chen, X.
Liu, C.
Zhang, X.
Xu, J.
Zhang, J.
Shi, S.
Wei, M.
Li, J.
Liu, R.
Gao, S.
Xu, L.
Sheng, Z.
Lian, J.
Shi, Q.
ANNALS OF ONCOLOGY, 2023, 34 : S901 - S902
[49] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
Jiang, Yuan
Li, Yue
Wang, Larry X. W.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (02) : 499 - 506
[50] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
Yuan Jiang
Yue Li
Larry X. W. Wang
International Journal of Clinical Pharmacy, 2022, 44 : 499 - 506

← 1 2 3 4 5 →